EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens



Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens



Journal of Immunology Research 2014: 827827-827827



Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

(PDF same-day service: $19.90)

Accession: 055116768

Download citation: RISBibTeXText

PMID: 24860838

DOI: 10.1155/2014/827827



Related references

Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63(3): 252-258, 2004

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. Journal Of Experimental Medicine. 187(8): 1349-1354, Il 20, 1998

Humoral immune response to p90 and other tumor-associated antigens in prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 360-361, July, 2003

A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage display. Cancer Detection and Prevention 30(3): 248-256, 2006

Irradiated apoptotic prostate cancer cells are a good source for prostate tumor associated antigens A rationale for a new approach for prostate cancer immunotherapy. Journal of Urology 167(4 Supplement): 53, April, 2002

Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. American Journal of Pathology 176(4): 1959-1972, 2010

Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades. Georgian Medical News: 34-38, 2007

T cells derived from patients with prostate cancer secrete IFNgamma in response to stimulation with prostate cancer antigens. Proceedings of the American Association for Cancer Research Annual Meeting (41): 880, March, 2000

Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Research 66(1): 6-9, 2006

A novel approach for the identification of prostate and tumor specific antigens in prostate cancer. Journal of Urology 163(4 Suppl ): 37, April, 2000

Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiology, Biomarkers & Prevention 12(2): 136-143, 2003

Evaluation of diagnostic value in using a panel of multiple tumor-associated antigens for immunodiagnosis of cancer. Journal of Immunology Research 2014: 512540-512540, 2015

Reduced semen quality in chronic prostatitis patients that have cellular autoimmune response to prostate antigens. Human Reproduction 20(9): 2567-2572, 2005

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. Journal of Molecular Medicine 87(5): 507-514, 2009

Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Journal of Molecular Medicine 84(11): 911-918, 2006